Table 2.
Antibacterial and anti-biofilm activity of the most active compounds against S. aureus ATCC 25923 and S. aureus Newman strains.
| Cmpd | Planktonic bacteria | MBIC µM [mg/L] | Anti-biofilm activity—IC50 (µM)a | Log Rb log10 (CFU/mL) | ||
|---|---|---|---|---|---|---|
| MIC µM [mg/L] | MBC µM [mg/L] | Pre-exposure | Post-exposure | |||
| Staphylococcus aureus ATCC 25923 | ||||||
| 9e | 40 [14.9] | 80 [29.9] | 40 [14.9] | 11.6 (9.9–13.3) | 23.3 (16.5–37.3) | 2.3 |
| 10d | 60 [18.9] | 120 [37.8] | 60 [18.9] | 23.6 (19.6–28.9) | 54.9 (50.8–59.1) | 2.8 |
| 10e | 60 [19.7] | 120 [39.5] | 60 [19.7] | 16.8 (14.4–20.1) | 51.8 (48.3–55.7) | 2.6 |
| Staphylococcus aureus Newman | ||||||
| 9e | 40 [14.9] | 60 [22.4] | 40 [14.9] | 29.4 (27.8–30.5) | 31.9 (26.0–38.0) | 1.8 |
| 10d | 60 [18.9] | 90 [28.3] | 60 [18.9] | 38.4 (36.6–41.2) | 62.0 (57.8–74.4) | 3.6 |
| 10e | 60 [19.7] | 90 [29.6] | 60 [19.7] | 37.3 (33.9–43.4) | 44.8 (38.5–53.8) | 2.3 |
aThe 95% confidence interval are shown in parentheses.
bLogarithm of reduction of biofilm burden on a pregrown biofilm. Compounds were tested at 100 µM.